BACKGROUND: Tissue microarray (TMA) analysis is a high-throughput approach that allows the screening of large tumor collectives for cytogenetic aberrrations. In this study, a TMA of a large collection of clinically well-defined primary squamous cell carcinomas of the head and neck (HNSCC) was used to determine the expression of several oncoproteins. MATERIALS AND METHODS: A TMA containing 547 primary HNSCC was used for the analysis of cyclinD1, c-myc, erbb1 and erbb2 expression by immunohistochemistry (IHC). RESULTS: CyclinD1 and c-myc were overexpressed at higher frequencies in primary pharyngeal and laryngeal carcinomas compared with primary oral carcinomas (p < 0.001 and p < 0.001), while erbb1 and erbb2 overexpression was associated with oral site (p < 0.001 and p = 0.04, respectively). Furthermore, cyclinD1 overexpression correlated with stage IV primary carcinomas (p = 0.04). CONCLUSION: HNSCC is a heterogenous group of tumors, which, depending on anatomic sites and clinical stage, shows variable expressions of the oncoproteins described. This indicates a specific pathogenic role of these oncoproteins in different subtypes of HNSCC and may have therapeutic implications.
BACKGROUND: Tissue microarray (TMA) analysis is a high-throughput approach that allows the screening of large tumor collectives for cytogenetic aberrrations. In this study, a TMA of a large collection of clinically well-defined primary squamous cell carcinomas of the head and neck (HNSCC) was used to determine the expression of several oncoproteins. MATERIALS AND METHODS: A TMA containing 547 primary HNSCC was used for the analysis of cyclinD1, c-myc, erbb1 and erbb2 expression by immunohistochemistry (IHC). RESULTS:CyclinD1 and c-myc were overexpressed at higher frequencies in primary pharyngeal and laryngeal carcinomas compared with primary oral carcinomas (p < 0.001 and p < 0.001), while erbb1 and erbb2 overexpression was associated with oral site (p < 0.001 and p = 0.04, respectively). Furthermore, cyclinD1 overexpression correlated with stage IV primary carcinomas (p = 0.04). CONCLUSION: HNSCC is a heterogenous group of tumors, which, depending on anatomic sites and clinical stage, shows variable expressions of the oncoproteins described. This indicates a specific pathogenic role of these oncoproteins in different subtypes of HNSCC and may have therapeutic implications.
Authors: K M Sathyan; R Sailasree; R Jayasurya; K Lakshminarayanan; Thomas Abraham; K R Nalinakumari; Elizabeth K Abraham; S Kannan Journal: J Cancer Res Clin Oncol Date: 2006-06-10 Impact factor: 4.553
Authors: V Häyry; L K Mäkinen; T Atula; H Sariola; A Mäkitie; I Leivo; H Keski-Säntti; J Lundin; C Haglund; J Hagström Journal: Br J Cancer Date: 2010-02-09 Impact factor: 7.640
Authors: Julie C Nienstedt; Alexander Gröbe; Patrick Lebok; Franziska Büscheck; Till Clauditz; Ronald Simon; Asmus Heumann; Guido Sauter; Christoph Moebius; Adrian Münscher; Rainald Knecht; Marco Blessmann; Max Heiland; Christina Pflug Journal: Clin Oral Investig Date: 2016-07-21 Impact factor: 3.573
Authors: Paul M Weinberger; Mark Merkley; Jeffrey R Lee; Bao-Ling Adam; Christine G Gourin; Robert H Podolsky; Bruce G Haffty; Evangelia Papadavid; Clarence Sasaki; Amanda Psyrri; William S Dynan Journal: Arch Otolaryngol Head Neck Surg Date: 2009-07